Nabil F. Saba on Muck Rack

Nabil F. Saba

Atlanta
As seen in: Hello Monday with Jessi Hempel, Color Research & Application, Nature, Wiley Online Library, PLOS ONE, MDPI, JAMA Network, JAMA Oncology, Science Magazine, The Lancet and
Director of Head & Neck Oncology, Vice Chair at @WinshipAtEmory. Medical Oncologist; H&N; cancer expert. Opinions=my own bit.ly/1x6xQ5H
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Nabil F.

Contact Nabil F., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A phase 1 study of berzosertib (M6620, VX-970) in combination with cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma (ETCTN 9950)

|
By Aarti K. Bhatia, Zhengjia Chen, Yuji Zhang, Justine Yang Bruce, Susanne Arnold, Jonathan W. Riess, Barbara Burtness, Nabil F. Saba, Conor E. Steuer, Dong M. Shin, Garrett T. Wasp, Thomas Davis, Moon Fenton, Harold Tara
| Wiley Online Library Verified
INTRODUCTION Squamous cell cancers of the head and neck (HNSCC) are a heterogenous group of malignancies, most commonly involving the mucosal oral cavity, oropharynx, hypopharynx, and larynx, caused by exposure to tobacco and other carcinogens or by the human papillomavirus (HPV).1 HNSCC is one of the most frequently diagnosed cancers worldwide, accounting for approximately 800,000 new cases and 400,000 deaths in 2022.2 Approximately 60%–70% of HPV+ and HPV– HNSCC patients present with...
Open in Who Shared Issue with article?

Integrating systemic therapy into larynx preservation: Lessons from 3 decades of progress

|
By José A. Monteiro, Yong Teng, Nicole C. Schmitt, Nabil F. Saba
| Wiley Online Library Verified
CONFLICT OF INTEREST STATEMENT Nicole C. Schmitt reports consulting for GeoVax, Regeneron, Johnson & Johnson, Sensorion, Synergy Research, and Aspargo Laboratories, and receiving research funding from Taiho Oncology and Astex Pharmaceuticals. Nabil F.
Open in Who Shared Issue with article?

Non-canonical dihydrolipoyl transacetylase promotes chemotherapy resistance via mitochondrial tetrahydrofolate signaling - Nature Communications

|
By Nabil F. Saba, Cheng-Kui Qu, Haian Fu, Suresh S. Ramalingam, Andrey Ivanov, Taro Hitosugi
| Nature Verified
Abstract Chemotherapy is often a primary treatment for cancer. However, resistance leads to therapeutic failure. Acetylation dynamics play important regulatory roles in cancer cells, but the mechanisms by which acetylation mediates therapy resistance remain poorly understood.
Open in Who Shared Issue with article?
See all 28 licensed articles (56 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified